eligibility_summary
Inclusion: Advanced/metastatic solid tumor with no SOC options, measurable disease, tissue available, life ≥12 wks, ECOG 0–1, adequate organs, contraception. Exclusion: Active/symptomatic CNS mets, active infection, serious lung/GI/cardiac/autoimmune disease or bleeding risk, recent anticancer therapy, immunosuppression, transfusion, major surgery or live vaccine, prior IL‑2R drugs or transplant, unresolved ≥G2 AEs (except alopecia/grade 2 neuropathy), HBV/HCV/HIV+, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05650242 tests BA1106, a human anti-CD25 monoclonal antibody (immunotherapy) in advanced solid tumors. BA1106 targets CD25 (IL-2 receptor alpha), highly expressed on regulatory T cells (Tregs) and transiently on activated T cells. Mechanism: blocks IL-2/IL-2R signaling and may deplete CD25+ Tregs via Fc-mediated effector functions (e.g., ADCC), aiming to reduce tumor-associated immunosuppression and enhance antitumor immunity. Administered IV as single agent in dose escalation (Q3W) and expansion (Q3W or Q2W). Primary targets: CD25+ Tregs in the tumor microenvironment and the IL-2/IL-2R signaling axis. Preliminary efficacy, safety, and PK are assessed.